Establishment of a green fluorescent protein tracing murine model focused on the functions of host components in necrosis repair and the niche of subcutaneously implanted glioma
- Authors:
- Published online on: November 27, 2013 https://doi.org/10.3892/or.2013.2873
- Pages: 657-664
Abstract
Introduction
The most common type of brain tumor in adults is glioma, which is extraordinarily lethal and is associated with extremely low survival rates (1,2). For most malignant forms of glioma, the median overall survival is only 12–15 months (2). The most common as well as the most aggressive type of glioma is glioblastoma multiforme (1). Glioblastoma multiforme consists of heterogeneous types of cells which demonstrate a variety of tumorigenic properties (1).
Gliomas arise from neural stem cells and progenitors (1). These neural stem cells are a subtype of astrocytes and are located in the two main regions of the brain where neurogenesis takes place: the subventricular region and the subgranular zone of hippocampal formation (2,3).
After cancer cells begin to propagate, they construct their own microenvironment or niche (1). In this niche there is ‘crosstalk’ between the tumor and the host so that the niche and its surroundings constantly interact (1,4).
One condition that promotes tumor growth is hypoxia (5). Rapid growth of a tumor that outpaces neovascularization results in a hypoxic niche (1). Hypoxia-inducible factor 1 (HIF-1) is an important regulator of cellular responses to hypoxia (5). HIF-1 promotes glioma growth, mainly by activating angiogenesis and by upregulating relevant target genes (5).
Animal models are critical for investigating malignant tumors. The orthotopic xenograft mouse model of glioblastoma has been particularly valuable for analyzing the characteristics of donor human tumor cells, but studies concerning the role of host tissue and cells are sparse (6). Due to the progress achieved in the research of cancer stem cells and the tumor microenvironment (7), it has become obviously necessary to have a comprehensive understanding of the role of host-derived tissues and cells in tumor development. In recent years, green fluorescent protein (GFP) nude mice have been widely adopted for human cancer xenograft models with the main focus on the tracing of tumor cells in the xenografts (8,9). The aims of the present study were to develop a subcutaneous xenograft GFP nude mouse model by injection of human glioma stem/progenitor cell line SU3, and investigating the potential roles of host cells in the repair of necrosis in xenografts. We successfully established a model that facilitates the observation of how host cells participate in the repair of tumor necrosis.
Materials and methods
Materials
The human glioma stem/progenitor cell line SU3 was established according to previously published methods from a surgical specimen of an adult male patient diagnosed with glioblastoma multiforme (10). In the present study, the human glioma stem/progenitor cell line SU3 was successfully obtained from fresh surgical specimens of GBM patients. These patients underwent surgery at the Neurosurgical Department, Second Affiliated Hospital of Suzhou University. The present study was approved by the Medical Review Board of the Suzhou University Medical School. The patients or their legal guardians provided informed consent for the use of their surgical specimen in research prior to sample acquisition. GFP nude NC-C57BL/6J mice were bred and maintained in a specific pathogen-free animal care facility. Animal experiments were approved by the Medical Review Board of Suzhou University Medical School, and all procedures were conducted in accordance with Chinese laws governing animal care. The trocars, namely #8 anesthesia epidural puncture needles (Zhejiang Haisheng Medical Instrument Co., Ltd., Hangzhou, China) were selected for the passage of tumor tissue in vivo. A fluorescence flashlight and fluorescence glasses were provided by NightSea Co. (http://www.nightsea.com/fplights.htm). The frozen sections of the xenografts were observed by fluorescence microcopy (Carl Zeiss Axio Observer A1; Thornwood, New York, USA). Immunohistochemical antibodies against TNF-1α (ab1793), HIF-1α (ab8366), Ki-67 (ab92742), CD68 (ab53444) and CD11b (ab64347) were purchased from Abcam (Cambridge, UK).
Tumor xenograft model
The human glioma stem/progenitor cell line SU3 was successfully obtained from fresh surgical specimens of GBM patients. SU3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS) and incubated at 37ºC in 98% humidified air containing 5% CO2. The SU3 cells in logarithmic growth phase in vitro were digested into a single-cell suspension liquid, and the final cell density was adjusted to 1×105/ml. A cell suspension, 150 μl per mouse, was slowly and smoothly injected subcutaneously into the right forelimb axilla of the GFP nude mice. The implanted tumor tissue was dissected free of blood clots, washed and minced into 0.5-mm slices for tumor tissue grafting. For the tumor tissue transplantation, we designed a simple but novel injection system, which included a 24# trocar and a specially designed propeller (1). The tumor tissue, 1 mm3 per mouse, was slowly and smoothly injected into the right forelimb axilla of the GFP nude mice. The animal model established through tumor tissue injection was regarded as the first generation in the present study. The implanted tumors were passed from animal to animal following the same procedure for 10 generations, which was the point at which model stability was established. The short diameter (a) and long diameter (b) of the xenografts were measured with calipers every 3 days, and the tumor volume was calculated according to the equation: V (mm3) = a2 × b/2. When cachexia occurred, the tumor-bearing mice were sacrificed for tumor removal and examination.
Molecular pathology and GFP expression of the tumors
We performed immunohistochemical staining to examine the expression of tumor necrosis factor (TNF) (1:50), hypoxia-inducible factor 1α (HIF-1α) (1:200), Ki-67 (1:1,000), CD68 (1:200) and CD11b (1:400) in the xenografts (1). The tumor-bearing mice and the subcutaneous xenografts were examined with a fluorescence flashlight and fluorescence glasses. Cells expressing GFP in the tumor tissue were examined using 5-μm frozen sections by fluorescence microscopy at a wavelength of 470 nm.
Results
General characteristics of the xenografts
In the primary xenograft models (SU3 cell suspension injection), although the tumorigenicity rate was 100% (5/5), there existed obvious individual differences in incubation period and tumor volume. In conjunction with the tumor passage through tumor tissue injection, these differences gradually narrowed, and the animal model became reliable beginning with the 7th generation. Subcutaneous seeded tumors can grow quite large; the xenograft volume of the 9th generation, one month after inoculation, was ~9.96±4.19 cm3 (n=10) in average and the implanted tumors continued to grow for more than 2 months. When all the tumor-bearing mice were sacrificed in the late stage (approximately 2 months after tumor inoculation), the tumor weight reached almost one half of the body weight of the mice, namely, 11.23±3.72 g (n=10).
Under a fluorescence flashlight, the tumor-bearing mice and the xenografts appeared green in color (Fig. 1A and B). Viewed with the naked eye under natural light, there was enlargement of the xenografts, and cutaneous vessels of the skin covering tumors were gradually increased in size, meeting the demand of the blood supply required by the rapidly growing tumor tissue (Fig. 1C and D). In the middle stage of xenograft growth, ischemic necrosis, even to the extent of ulceration, was observed in the local skin, possibly indicating the insufficiency of the blood supply to the implanted tumors (Fig. 1E); there was still fresh tissue in the tumor base (Fig. 1F).
Histopathologic characteristics of the xenografts
In the xenograft tumor sections stained with hematoxylin and eosin (H&E), hyperchromatic nuclei, relatively less cytoplasm, heteromorphic nuclei and regional densely arranged tumor cells were observed (Fig. 2). Necrotizing hemorrhage was frequently observed in the xenograft sections and was divided into fresh hemorrhage and old hemorrhage (Fig. 2A). In the fresh hemorrhagic foci, a large number of collapsing red blood cells could still be observed. In the old hemorrhagic areas, two scenes were observed: i) red blood cells disappeared while some inflammatory cells were observed; and ii) there were no inflammatory cells, however, tumor cells with relatively few mesenchymal components were noted growing around the vessels. Generally, the xenograft tumors were rich in blood vessels, but a vast majority of new blood vessels lacked complete vascular structure. Only a few large vessels possessed a nearly intact vascular wall. In rare instances, clusters of nucleated cells were noted in the vascular lumen. Tumor cells could be seen invading soft tissue and muscle fiber (Fig. 2D).
Molecular pathology of the xenografts
Hypoxia-inducible factor 1α was strongly expressed in the nuclei of the tumor cells (Fig. 3A and B). Generally, the expression of HIF-1α was high in the central portion of the tumor and low in the marginal zones (Fig. 3C and D); however, notably, invasive tumor cells migrating from the marginal zones also highly expressed HIF-1α (Fig. 4). In the necrotic areas of the tumors, TNF was mainly expressed in shapeless intercellular fluid; however, in the non-necrotic areas of the tumors, TNF was diffusedly expressed on the membrane of tumor cells rather than in the intercellular fluid (Fig. 5). The vast majority of tumor cells, regardless of cell type, including those in the necrotic areas, strongly expressed Ki-67 in the nuclei (Fig. 6). In old hemorrhagic areas, the majority of cells were positively stained for CD11b and CD68, which were expressed both in the cytoplasm and on the membrane (Fig. 7).
Green fluorescence components in the xenografts
As the host organs, tissues and cells were GFP-expressing, all components in the xenografts displayed green fluorescence under fluorescence microscopy at an excitation wavelength of 470 nm and were regarded to be derived from the host. At the same time, tumor cells did not stimulate green fluorescence under fluorescence microscopy at an excitation wavelength of 470 nm. Based on this concept, it was obvious that the implanted tumors were covered by host-derived skin, and the green area surrounding the tumor mass mainly consisted of host components (Fig. 1A and B). Notably, a large number of GFP-expressing cells were found clustered in the necrotic areas of the tumors (Fig. 8). GFP-expressing cells that had a similar appearance to macrophagocytes were also found scattered among the tumor parenchyma (Fig. 9).
Discussion
In the present study, we developed an animal model for studying the role of host cells in glioma. We used a subcutaneous xenograft GFP nude mouse model and passed implanted tumors from animal to animal for 10 generations. The xenografts, which came from the human glioma stem/progenitor cell line SU3, were rich in blood vessels, necrosis and hemorrhagic foci. In the interstitial tissue of the host, we noted numerous cells expressing GFP, CD68 and CD11b. Based on our findings we believe this model has significant potential for application in the future research of tumor tissue remodeling and the tumor niche.
Hypoxia inducible factor 1α (HIF-1α)
Hypoxia-inducible factor 1 plays an important role in tumor growth by being a key regulator of cellular responses to hypoxia (5,11,12). It consists of α and β subunits (5). In hypoxic conditions, the α subunit is stable and in normoxia it is rapidly degraded (5). HIF-1 is translocated to the cell nucleus and induces transcription of its downstream target genes such as vascular endothelial growth factor and erythropoietin.
Hypoxia-inducible factor 1 has been reported to play an important role in tumor growth and metastasis by regulating energy metabolism and inducing angiogenesis to allow survival in cellular hypoxia. Increased levels of HIF-1 have been noted in breast carcinogenesis, lung cancer, prostatic cancer, gastric carcinoma and cervical cancer (13–16). Therefore, it was necessary to evaluate the expression of HIF-1 in the assessment of our animal model. HIF-1 expression in our tumor model showed two features: i) HIF-1α was highly expressed in the central portion of the tumor and expression was low in the tumor margin which was mainly due to low oxygen conditions in the central portion of the tumor (17); and ii) tumor cells invading the host tissue where oxygen is sufficient also highly expressed HIF-1. We conjecture that the high expression of HIF-1 in non-hypoxic host tissue was associated with the disorder of tumor-suppressor genes (18). With regard to expression of HIF-1, this tumor animal model meets the required criterion.
Expression of tumor necrosis factor (TNF)
Tumor necrosis factor was originally discovered in hemorrhagic necrotic tissue removed from tumor-bearing mice. TNF, which consists of TNF-α and TNF-β, was found to be secreted by macrophages and leukomonocytes. TNF-α is a type II membrane protein and contains soluble TNF-α and membrane-related TNF-α. The effect of TNF-α is concentration-dependent and type-dependent, including the induction of tumor cell apoptosis (19) and immune surveillance (20) or the effects are opposite depending on dose. For example, at high doses, TNF exerts a degenerative effect on tumor vasculature and induces tumor hemorrhage and necrosis; at moderate doses, TNF does not have cytotoxic effects on tumor cells, but stimulates the proliferation and metastasis of tumor cells by inducing angiogenesis and promoting secretion of matrix metalloproteinase and endothelial adhesion molecule (21,22). In tumor necrotic areas of our animal model, TNF appeared to have the characteristic of sTNF-α; it was highly expressed in shapeless intercellular fluid, distributed lamellarly and without specific cell morphology. As there were numerous immune cells infiltrating into tumor necrotic areas, sTNF-α was most likely secreted by these immune cells (Fig. 8). Nevertheless, in the non-necrotic areas of the tumors, TNF appeared to have the characteristic of mTNF-α; it was diffusely expressed on the membrane of tumor cells. For this reason, mTNF-α was possibly secreted by tumor cells. In brief, the expression of TNF-α in this subcutaneous GFP nude mouse model conformed to the features of malignant tumors.
Tumor microenvironment
The tumor microenvironment, also called the tumor niche, is composed of interstitial fluid and various types of cells (inflammatory cells, endothelial cells and fibroblasts). It is known that in the early stage, the host-derived microenvironment exerts suppressive effects on the growth of transplanted tumors due to transplant rejection; however, in conjuction with the growth of transplanted tumors, the microenvironment changes in favor of tumor growth. This phenomenon has become a topic of extreme importance in oncology research during the last few decades. In the early years of research, Bettinger et al (23) reported that microglia can promote glioma migration and Markovic et al (24) reported that when microglia were selectively depleted, the invasiveness of tumors was significantly decreased. In recent years, Wu et al (25) reported that macrophages/microglia have the potential to promote the proliferation of tumor cells. Straussman et al (26) reported that when co-cultured with stromal cells, tumor cells become more resistant in vitro to chemotherapy. Taken together, these studies indicate that the host-derived tumor microenvironment plays a critical role in tumor development and progression. In another in vitro study of the tumor microenvironment, Borovksi et al (27) used a co-culture system comprising primary brain tumor microvascular endothelial cells and glioma propagating cells obtained from glioblastoma multiforme biopsies. They found that glioma propagating cells had higher proliferation rates when co-cultured with primary brain tumor microvascular endothelial cells than when cultured alone. However, in vitro experiments are lacking in the ability to demonstrate the importance of the tumor microenvironment.
In vivo experiments were performed by Najbauer et al (4) who used orthotopic rodent models of human glioma xenografts and reported that a large number of host cells expressing nestin migrate to glioma and contribute to the growth of the xenograft by assembling into the microvasculature of glioma. It was determined that the host cells originated from the subventricular zone ipsilateral to the xenografts. The advantage of the GFP nude mouse model established in the present study is that it is convenient for tracing host cells and investigating the role of host cells in tumor growth. For example, a large amount of GFP-expressing cells were found clustered in old necrotic areas, and the majority of cells expressed CD11b and CD68, which are inflammatory cells that can serve as markers for macrophage-specific cells. Thus, we deduced that host cells are critical component of the tumor microenvironment that play a role in the repair of tumor necrosis. As determined by the immunochemical staining, numerous TNF-α immune complexes were noted in the necrotic areas of the tumors (Fig. 5). This indicated that TNF-α secreted by macrophages participates in the composition of the cell factor microenvironment. A large number of cells expressing Ki-67 was noted in both the tumor necrotic areas and non-necrotic areas (Fig. 6). Ki-67 is a nuclear proliferation antigen and its expression reflects the proliferative ability of cells, and for tumor cells its expression also predicts malignancy and poor prognosis. Since Ki-67-expressing cells included GFP cells, this added more evidence to support the assumption that host-derived cells are involved in the repair of tumor necrosis. Due to the participation of host cells in the repair of necrosis of tumor tissue, no cyst was discovered in our more than 100 tumor specimens.
de Almeida Sassi et al (1) recently reviewed studies on glioma including the extensive research that has been carried out to describe the tumor microenvironment. Importantly, they revealed that there is a reciprocal relationship between glioma stem cells and their microenvironment; that is, glioma stem cells can modulate the microenvironment that produces signals that regulate glioma stem cells. They also pointed out that tumor microvasculature generates niches that promote the establishment and maintainence of brain tumor stem cells. In addition, niches were found to have an important role in protecting these stem cells from environmental insults (e.g., chemotherapeutic agents). Recently, Gazdzinski and Neiman (28) injected GL261 and 4C8 glioma cells that were labeled with iron oxide particles or with a fluorescent probe into the brains of synergeneic mice. Following tumor development, they used texture analysis to analyze the label distribution patterns in the two types of gliomas. They reported that in the GL261 tumors the label was observed mainly in the tumor core whereas in the 4C8 tumors the label was more randomly distributed throughout the tumor. They speculated that differences in the label distribution maps between the two different types of gliomas were likely affected by differences in the tumor microenvironment.
In conclusion, a glioma model consisting of GFP nude mice as the host was successfully established. With this model, we were easily able to observe how host cells participate in tumor necrosis repair. Since the host cells constantly express GFP, this model has great potential for investigating the tumor microenvironment as a supporting role in tumor growth and progression and may serve to identify future therapeutic targets.
Acknowledgements
The present study was funded by the National Natural Scientific Foundation of China (nos. 81071766; 81172400; 81272799; and 81272793).
References
de Almeida Sassi F, Brunetto AL, Schwartsmann G, Roesler R and Abujamra AL: Glioma revisited: from neurogenesis and cancer stem cells to the epigenetic regulation of niche. J Oncol. 2012:5378612012. View Article : Google Scholar | |
He H, Li MU and Niu CS: The pathological characteristics of glioma stem cell niches. J Clin Neurosci. 19:121–127. 2012. View Article : Google Scholar | |
Tavazoie M, Van der Veken L, Silva-Vargas V, et al: A specialized vascular niche for adult neural stem cells. Cell Stem Cell. 3:279–288. 2008. View Article : Google Scholar : PubMed/NCBI | |
Najbauer J, Huszthy PC, Barish ME, et al: Cellular host responses in gliomas. PLoS One. 7:e351502012. View Article : Google Scholar : PubMed/NCBI | |
Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ and Van Meir EG: Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol. 7:134–153. 2005. View Article : Google Scholar : PubMed/NCBI | |
Fei XF, Zhang QB, Dong J, et al: Development of a clinically relevant orthotopic xenograft mouse model of metastatic lung cancer and glioblastoma through surgical tumor tissue injection with trocar. J Exp Clin Cancer Res. 29:842010. View Article : Google Scholar | |
Charles NA, Holland EC, Gilbertson R, Glass R and Kettenmann H: The brain tumor microenvironment. Glia. 60:1169–1180. 2011. View Article : Google Scholar | |
Hoffman RM: Green fluorescent protein imaging of tumor cells in mice. Lab Animal. 31:34–41. 2002.PubMed/NCBI | |
Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN and Canoll P: Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia. 53:799–808. 2006. View Article : Google Scholar : PubMed/NCBI | |
Wan Y, Fei XF, Wang ZM, et al: Expression of miRNA-125b in the new highly invasive glioma stem cell and progenitor cell line SU3. Chin J Cancer. 31:207–214. 2012. View Article : Google Scholar : PubMed/NCBI | |
Gillespie DL, Whang K, Ragel BT, Flynn JR, Kelly DA and Jensen RL: Silencing of hypoxia inducible factor-1α by RNA interference attenuates human glioma cell growth in vivo. Clin Cancer Res. 13:2441–2448. 2007. | |
Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM and Johnson RS: Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res. 60:4010–4015. 2000. | |
Bos R, Van der Groep P, Greijer AE, et al: Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 97:1573–1581. 2003. | |
Zhong H, Semenza GL, Simons JW and De Marzo AM: Up-regulation of hypoxia-inducible factor 1α is an early event in prostate carcinogenesis. Cancer Detect Prev. 28:88–93. 2004. | |
Birner P, Schindl M, Obermair A, Plank C, Breitenecker G and Oberhuber G: Overexpression of hypoxia-inducible factor 1 α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60:4693–4696. 2000. | |
Urano N, Fujiwara Y, Doki Y, et al: Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer. 9:44–49. 2006. View Article : Google Scholar : PubMed/NCBI | |
Clottes E: Hypoxia inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy. Bull Cancer. 92:119–127. 2005.(In French). | |
Xia Y, Choi HK and Lee K: Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem. 49:24–40. 2012. View Article : Google Scholar : PubMed/NCBI | |
Lyu MA and Rosenblum MG: The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1. Mol Cancer Ther. 4:1205–1213. 2005. View Article : Google Scholar : PubMed/NCBI | |
Ebert LM, Meuter S and Moser B: Homing and function of human skin γδ T cells and NK cells: relevance for tumor surveillance. J Immunol. 176:4331–4336. 2006. | |
Warren MA, Shoemaker SF, Shealy DJ, Bshara W and Ip MM: Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice. Mol Cancer Ther. 8:2655–2663. 2009. View Article : Google Scholar | |
Yin Y, Chen X and Shu Y: Gene expression of the invasive phenotype of TNF-α-treated MCF-7 cells. Biomed Pharmacother. 63:421–428. 2009. | |
Bettinger I, Thanos S and Paulus W: Microglia promote glioma migration. Acta Neuropathol. 103:351–355. 2002. View Article : Google Scholar : PubMed/NCBI | |
Markovic DS, Glass R, Synowitz M, Rooijen Nv and Kettenmann H: Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J Neuropathol Exp Neurol. 64:754–762. 2005. View Article : Google Scholar : PubMed/NCBI | |
Wu A, Wei J, Kong LY, et al: Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 12:1113–1125. 2010. View Article : Google Scholar : PubMed/NCBI | |
Straussman R, Morikawa T, Shee K, et al: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 487:500–504. 2012. View Article : Google Scholar : PubMed/NCBI | |
Borovski T, Verhoeff JJC, ten Cate R, et al: Tumor microvascular supports proliferation and expansion of glioma-propagating cells. In J Cancer. 125:1222–1230. 2009.PubMed/NCBI | |
Gazdzinski LM and Nieman BJ: Cellular imaging and texture analysis distinguish differences in cellular dynamics in mouse brain tumors. Magn Reson Med. May 9–2013. View Article : Google Scholar |